Iron Chelation in Thalassemia Major

被引：6

作者：

Bista, Sudeep R. ^{[1
,2
,3
,4
]}

Haywood, Alison ^{[1
,2
,3
,4
]}

Norris, Ross ^{[1
,2
,3
,4
]}

Good, Phillip ^{[2
,5
,6
]}

Tapuni, Angela ^{[7
]}

Lobb, Michael ^{[8
]}

Hardy, Janet ^{[2
,5
]}

机构：

[1] Griffith Univ, Sch Pharm, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia

[2] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia

[3] St Vincents Hosp, SydPath, Sydney, NSW 2010, Australia

[4] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW, Australia

[5] Mater Hlth Serv, Dept Palliat & Support Care, Brisbane, Qld, Australia

[6] St Vincents Private Hosp, Palliat Care, Brisbane, Qld, Australia

[7] Mater Hlth Serv, Dept Palliat & Support Care, Brisbane, Qld, Australia

[8] Mater Pathol Serv, South Brisbane, Qld, Australia

来源：

CLINICAL THERAPEUTICS | 2015年 / 37卷 / 12期

关键词：

iron chelators; iron overload; labile plasma iron; Thalassemia major;

D O I：

10.1016/j.clinthera.2015.11.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Purpose: Iron chelation has improved survival and quality of life of patients with thalassemia major. there are currently 3 commercially available iron-chelating drugs with different pharmacokinetic and pharmacodynamic activity. The choice of adequate chelation treatment should be tailored to patient needs and based on up-to-date scientific evidence. Methods: A review of the most recent literature was performed. Findings: The ability of the chelators to bind the redox active component of iron, labile plasma iron, is crucial for protecting the cells. Chelation therapy should be guided by magnetic resonance imaging that permits the tailoring of therapy according to the needs of the patient because different chelators preferentially clear iron from different sites. Normal levels of body iron seem to decrease the need for hormonal and cardiac therapy. (C) 2015 Elsevier HS Journals, Inc. All rights reserved.

引用

页码：2882 / 2883

页数：2

共 1 条

[1] Saliva versus Plasma for Pharmacokinetic and Pharmacodynamic Studies of Fentanyl in Patients with Cancer [J].

Bista, Sudeep R. ;

Haywood, Alison ;

Norris, Ross ;

Good, Phillip ;

Tapuni, Angela ;

Lobb, Michael ;

Hardy, Janet .

CLINICAL THERAPEUTICS, 2015, 37 (11) :2468-2475

← 1 →